

Scancell

Genmab strikes second GlyMab deal

4 December 2024

- Genmab has signed a second commercial licence with Scancell for a GlyMab antibody, confirming it was the unnamed international biotech company in the June 2024 evaluation deal, which allowed for seven months of exclusivity in return for a \$1m fee. While detailed terms have not been disclosed, Scancell is eligible to receive an upfront fee and potential development and commercialisation milestone payments up to a maximum of \$630m, as well as royalties on products sold. Genmab gains the exclusive global rights to develop and commercialise this GlyMab across defined modalities as multiple novel therapeutic products.
- The headline deal value of \$630m in total milestone potential suggests that this second licence may be similar to the first deal ([October 2022 Lighthouse](#)). In the first multi-product GlyMab deal with Genmab, Scancell received a \$6m upfront fee, potential milestones that could reach a maximum of \$624m across all modalities (with \$208m for each product), and a low single digit royalty on net sales of all commercialised products. Our [October 2024 Update](#) provides more detail on the GlyMab platform, and our [February 2023 Outlook](#) covers more information on Genmab and the first deal terms.
- The original October 2022 deal centred on SC129, a GlyMab that targets sialyl-di-Lewis^a, with high selectivity for pancreatic tumours (74%), gastric cancers (50%) and colorectal cancers (36%). Genmab has licenced SC129 for antibody drug conjugates (ADC), T cell bispecifics (TCB), and radio-immunotherapy applications. Lewis-based glycans have a very limited distribution on normal tissues and are over-expressed in cancers that occur in epithelial cells. We believe this second deal is also focused on solid tumours.
- GlyMabs are antibodies that target sugar motifs rather than proteins. Scancell has built a pipeline of differentiated anticancer mAbs, with five in preclinical development. This second deal with Genmab provides powerful validation of the scientific, clinical, and commercial appeal of the GlyMab platform.

Price	13.0p
Market Cap	£123.2m
Primary exchange	AIM
Sector	Healthcare
Company Code	SCLP
Corporate client	Yes

Company description:

Scancell is a clinical-stage immuno-oncology specialist that has four broadly applicable technology platforms. Two are therapeutic vaccines, Moditope and ImmunoBody, and two are antibody based, GlyMab and AvidiMab.

Trinity Delta view: Scancell has four distinct technology platforms: two highly promising oncology vaccine platforms (Moditope and ImmunoBody), and two antibody technologies (GlyMab and AvidiMab). Investor attention remains, understandably, focused on the vaccine programmes, notably further data from the ongoing SCOPE trial (Cohort 1 data in H125 and Cohort 3 data in H225) following much anticipated recent positive response rate data from Cohort 1 ([November 2024 Lighthouse](#)). Nonetheless, licencing of the second GlyMab antibody provides endorsement of Scancell's ability to generate commercially relevant therapeutics, deepens the relationship with antibody expert Genmab, and demonstrates the breadth of, and value inherent in, the GlyMab platform. In addition, the upfront payment, while not disclosed will provide immediate non-dilutive funding, with the potential for additional future near-to-mid-term milestones. Our current risk adjusted NPV valuation for Scancell is £311m, or 33p per share.

Analysts

Lala Gregorek

lgregorek@trinitydelta.org
+44 (0) 20 3637 5043

Philippa Gardner

pgardner@trinitydelta.org
+44 (0) 20 3637 5042

Philippa Gardner

pgardner@trinitydelta.org

+44 (0) 20 3637 5042

Lala Gregorek

lgregorek@trinitydelta.org

+44 (0) 20 3637 5043

Franc Gregori

fgregori@trinitydelta.org

+44 (0) 20 3637 5041

Disclaimer

Trinity Delta Research Limited ("TDRL"; firm reference number: 725161), which trades as Trinity Delta, is an appointed representative of Equity Development Limited ("ED"). The contents of this report, which has been prepared by and is the sole responsibility of TDRL, have been reviewed, but not independently verified, by ED which is authorised and regulated by the FCA, and whose reference number is 185325.

ED is acting for TDRL and not for any other person and will not be responsible for providing the protections provided to clients of TDRL nor for advising any other person in connection with the contents of this report and, except to the extent required by applicable law, including the rules of the FCA, owes no duty of care to any other such person. No reliance may be placed on ED for advice or recommendations with respect to the contents of this report and, to the extent it may do so under applicable law, ED makes no representation or warranty to the persons reading this report with regards to the information contained in it.

In the preparation of this report TDRL has used publicly available sources and taken reasonable efforts to ensure that the facts stated herein are clear, fair and not misleading, but make no guarantee or warranty as to the accuracy or completeness of the information or opinions contained herein, nor to provide updates should fresh information become available or opinions change.

Any person who is not a relevant person under section of Section 21(2) of the Financial Services & Markets Act 2000 of the United Kingdom should not act or rely on this document or any of its contents. Research on its client companies produced by TDRL is normally commissioned and paid for by those companies themselves ('issuer financed research') and as such is not deemed to be independent, as defined by the FCA, but is 'objective' in that the authors are stating their own opinions. The report should be considered a marketing communication for purposes of the FCA rules. It has not been prepared in accordance with legal requirements designed to promote the independence of investment research and it is not subject to any prohibition on dealing ahead of the dissemination of investment research. TDRL does not hold any positions in any of the companies mentioned in the report, although directors, employees or consultants of TDRL may hold positions in the companies mentioned. TDRL does impose restrictions on personal dealings. TDRL might also provide services to companies mentioned or solicit business from them.

This report is being provided to relevant persons to provide background information about the subject matter of the note. This document does not constitute, nor form part of, and should not be construed as, any offer for sale or purchase of (or solicitation of, or invitation to make any offer to buy or sell) any Securities (which may rise and fall in value). Nor shall it, or any part of it, form the basis of, or be relied on in connection with, any contract or commitment whatsoever. The information that we provide is not intended to be, and should not in any manner whatsoever be, construed as personalised advice. Self-certification by investors can be completed free of charge at www.fisma.org. TDRL, its affiliates, officers, directors and employees, and ED will not be liable for any loss or damage arising from any use of this document, to the maximum extent that the law permits.

Copyright 2024 Trinity Delta Research Limited. All rights reserved.

More information is available on our website: www.trinitydelta.org